We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
Read MoreHide Full Article
The Q1 reporting cycle is at its last lap with 358 S&P members (78.2% of the total market cap) having already reported their quarterly numbers. For Medical, one of the 16 broader Zacks sectors, we have results from 84.5% of total market cap.
Per the latest Earnings Outlook, so far this sector demonstrated a bullish trend with earnings and revenue beat standing at very impressive levels of 87.2% and 69.2%, respectively.
Medical Product Industry at a Glance
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment. Investors are bullish as the Zacks categorized Medical - Products industry registered growth of 8.8% in the last three months, comfortably outperforming the S&P 500 Index’s gain of 4.5%.
Notably, the growth story in the space exclusively pertains to the market dynamics and the shift in consumer demand, courtesy of the growing prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things. Furthermore, cost-effective products and techniques targeting emerging markets raise optimism.
On the flipside, the recent political conundrum in the healthcare space pertaining to the ‘Trumpcare’ is a headwind. Amid such unpredictability, let us take a look at how the players of this industry are positioned this earnings season.
Let’s take a look at the major Medical products stocks expected to release their first-quarter 2017 reports around May 8:
Integer Holdings Corporation (ITGR - Free Report) : It is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets.
However, our proven model does not conclusively show that Integer Holdings is likely to beat earnings this quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.
That is not the case here. The company currently carries a Zacks Rank #2 and has an Earnings ESP of -6.9%. Though a favorable Zacks Rank increases the predictive power of ESP, we need a positive ESP to be confident about an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Integer Holdings Corporation Price and EPS Surprise
Opko Health, Inc. (OPK - Free Report) : OPKO Health is a diversified healthcare company that seeks to establish industry leading position in large, rapidly growing markets. Its diagnostics business includes BioReference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business. However, our proven model does not conclusively show that the stock is likely to beat earnings this quarter as along with a Zacks Rank #4 (Sell), it has an Earnings ESP of 0.00%.
Nevro Corp. (NVRO - Free Report) : Nevro, a global medical device company that works on the improvement of the quality of life of patients suffering from debilitating chronic pain. Like with the above two, our proven model does not conclusively show that the stock is likely to beat earnings this quarter. This because along with a Zacks Rank #4 the stock has an Earnings ESP of 0.00%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
The Q1 reporting cycle is at its last lap with 358 S&P members (78.2% of the total market cap) having already reported their quarterly numbers. For Medical, one of the 16 broader Zacks sectors, we have results from 84.5% of total market cap.
Per the latest Earnings Outlook, so far this sector demonstrated a bullish trend with earnings and revenue beat standing at very impressive levels of 87.2% and 69.2%, respectively.
Medical Product Industry at a Glance
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment. Investors are bullish as the Zacks categorized Medical - Products industry registered growth of 8.8% in the last three months, comfortably outperforming the S&P 500 Index’s gain of 4.5%.
Notably, the growth story in the space exclusively pertains to the market dynamics and the shift in consumer demand, courtesy of the growing prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things. Furthermore, cost-effective products and techniques targeting emerging markets raise optimism.
On the flipside, the recent political conundrum in the healthcare space pertaining to the ‘Trumpcare’ is a headwind. Amid such unpredictability, let us take a look at how the players of this industry are positioned this earnings season.
Let’s take a look at the major Medical products stocks expected to release their first-quarter 2017 reports around May 8:
Integer Holdings Corporation (ITGR - Free Report) : It is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets.
However, our proven model does not conclusively show that Integer Holdings is likely to beat earnings this quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.
That is not the case here. The company currently carries a Zacks Rank #2 and has an Earnings ESP of -6.9%. Though a favorable Zacks Rank increases the predictive power of ESP, we need a positive ESP to be confident about an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Integer Holdings Corporation Price and EPS Surprise
Integer Holdings Corporation Price and EPS Surprise | Integer Holdings Corporation Quote
Opko Health, Inc. (OPK - Free Report) : OPKO Health is a diversified healthcare company that seeks to establish industry leading position in large, rapidly growing markets. Its diagnostics business includes BioReference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business. However, our proven model does not conclusively show that the stock is likely to beat earnings this quarter as along with a Zacks Rank #4 (Sell), it has an Earnings ESP of 0.00%.
Opko Health, Inc. Price and EPS Surprise
Opko Health, Inc. Price and EPS Surprise | Opko Health, Inc. Quote
Nevro Corp. (NVRO - Free Report) : Nevro, a global medical device company that works on the improvement of the quality of life of patients suffering from debilitating chronic pain. Like with the above two, our proven model does not conclusively show that the stock is likely to beat earnings this quarter. This because along with a Zacks Rank #4 the stock has an Earnings ESP of 0.00%.
Nevro Corp. Price and EPS Surprise
Nevro Corp. Price and EPS Surprise | Nevro Corp. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>